FALSE0001819790--12-312023Q1P3YP1YP1YP1Y0.333300018197902023-01-012023-03-3100018197902023-05-04xbrli:shares00018197902023-03-31iso4217:USD00018197902022-12-31iso4217:USDxbrli:shares0001819790tars:LicenseAndCollaborationMember2023-01-012023-03-310001819790tars:LicenseAndCollaborationMember2022-01-012022-03-3100018197902022-01-012022-03-310001819790us-gaap:CommonStockMember2022-12-310001819790us-gaap:AdditionalPaidInCapitalMember2022-12-310001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001819790us-gaap:RetainedEarningsMember2022-12-310001819790us-gaap:RetainedEarningsMember2023-01-012023-03-310001819790us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001819790us-gaap:CommonStockMember2023-01-012023-03-310001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001819790us-gaap:CommonStockMember2023-03-310001819790us-gaap:AdditionalPaidInCapitalMember2023-03-310001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001819790us-gaap:RetainedEarningsMember2023-03-3100018197902021-12-310001819790us-gaap:CommonStockMember2021-12-310001819790us-gaap:AdditionalPaidInCapitalMember2021-12-310001819790us-gaap:RetainedEarningsMember2021-12-310001819790us-gaap:RetainedEarningsMember2022-01-012022-03-310001819790us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001819790us-gaap:CommonStockMember2022-01-012022-03-3100018197902022-03-310001819790us-gaap:CommonStockMember2022-03-310001819790us-gaap:AdditionalPaidInCapitalMember2022-03-310001819790us-gaap:RetainedEarningsMember2022-03-31tars:segment0001819790srt:MinimumMember2023-01-012023-03-310001819790srt:MaximumMember2023-01-012023-03-31xbrli:pure0001819790srt:MinimumMembertars:EquityIncentivePlan2016Member2023-01-012023-03-310001819790srt:MaximumMembertars:EquityIncentivePlan2016Member2023-01-012023-03-310001819790tars:EquityIncentivePlan2016Member2023-01-012023-03-310001819790us-gaap:CashMemberus-gaap:FairValueInputsLevel1Member2023-03-310001819790us-gaap:FairValueInputsLevel2Memberus-gaap:CashMember2023-03-310001819790us-gaap:CashMemberus-gaap:FairValueInputsLevel3Member2023-03-310001819790us-gaap:CashMember2023-03-310001819790us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-03-310001819790us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-03-310001819790us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-03-310001819790us-gaap:MoneyMarketFundsMember2023-03-310001819790us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-03-310001819790us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-03-310001819790us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2023-03-310001819790us-gaap:USTreasurySecuritiesMember2023-03-310001819790us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2023-03-310001819790us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-03-310001819790us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2023-03-310001819790us-gaap:CommercialPaperMember2023-03-310001819790us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-03-310001819790us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-03-310001819790us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-03-310001819790us-gaap:CorporateDebtSecuritiesMember2023-03-310001819790us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-03-310001819790us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentDebtSecuritiesMember2023-03-310001819790us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-03-310001819790us-gaap:USGovernmentDebtSecuritiesMember2023-03-310001819790us-gaap:FairValueInputsLevel1Member2023-03-310001819790us-gaap:FairValueInputsLevel2Member2023-03-310001819790us-gaap:FairValueInputsLevel3Member2023-03-310001819790us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001819790us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-12-310001819790us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001819790us-gaap:MoneyMarketFundsMember2022-12-310001819790us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2022-12-310001819790us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2022-12-310001819790us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2022-12-310001819790us-gaap:USTreasurySecuritiesMember2022-12-310001819790us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2022-12-310001819790us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-12-310001819790us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2022-12-310001819790us-gaap:CommercialPaperMember2022-12-310001819790us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001819790us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001819790us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001819790us-gaap:CorporateDebtSecuritiesMember2022-12-310001819790us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001819790us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentDebtSecuritiesMember2022-12-310001819790us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001819790us-gaap:USGovernmentDebtSecuritiesMember2022-12-310001819790us-gaap:FairValueInputsLevel1Member2022-12-310001819790us-gaap:FairValueInputsLevel2Member2022-12-310001819790us-gaap:FairValueInputsLevel3Member2022-12-3100018197902021-03-012021-03-31tars:tranchetars:warrant00018197902022-01-012022-12-31tars:security0001819790srt:MinimumMembertars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2023-03-310001819790srt:MaximumMembertars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2023-03-310001819790tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2023-03-310001819790srt:MinimumMembertars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2022-12-310001819790srt:MaximumMembertars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2022-12-310001819790tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2022-12-310001819790us-gaap:FurnitureAndFixturesMember2023-03-310001819790us-gaap:FurnitureAndFixturesMember2022-12-310001819790us-gaap:OfficeEquipmentMember2023-03-310001819790us-gaap:OfficeEquipmentMember2022-12-310001819790us-gaap:OtherMachineryAndEquipmentMember2023-03-310001819790us-gaap:OtherMachineryAndEquipmentMember2022-12-310001819790us-gaap:LeaseholdImprovementsMember2023-03-310001819790us-gaap:LeaseholdImprovementsMember2022-12-310001819790tars:FollowOnPublicOfferingMember2022-05-012022-05-310001819790tars:FollowOnPublicOfferingMember2022-05-310001819790us-gaap:OverAllotmentOptionMember2022-05-012022-05-310001819790us-gaap:OverAllotmentOptionMember2022-06-012022-06-300001819790us-gaap:OverAllotmentOptionMember2022-06-300001819790tars:FollowOnPublicOfferingMember2022-05-012022-06-30tars:vote0001819790us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001819790us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001819790us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001819790us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001819790us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001819790us-gaap:RestrictedStockUnitsRSUMember2022-12-310001819790us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001819790us-gaap:RestrictedStockUnitsRSUMember2023-03-310001819790us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001819790us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001819790tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember2023-01-012023-03-310001819790tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember2022-01-012022-03-310001819790tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember2023-01-012023-03-310001819790tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember2022-01-012022-03-310001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2019-01-012023-03-310001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:ClinicalMilestonesMember2019-01-012023-03-310001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:ClinicalMilestonesMember2023-01-012023-03-310001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-03-310001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:CommercialAndSalesMilestonesMember2023-03-310001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-09-012020-09-300001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-09-300001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:ClinicalMilestonesMember2022-12-012022-12-310001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:ClinicalMilestonesMember2023-03-310001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:CommercialAndSalesMilestonesMember2023-03-31tars:contract0001819790srt:DirectorMember2021-12-310001819790srt:DirectorMember2021-12-312021-12-310001819790srt:MinimumMembersrt:DirectorMember2021-12-310001819790srt:MaximumMembersrt:DirectorMember2021-12-310001819790us-gaap:SubsequentEventMembersrt:ChiefFinancialOfficerMember2023-05-042023-05-040001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:LianBioMember2021-03-260001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:MilestoneDeterminedByTheCompanyMembertars:LianBioMember2021-03-260001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:LianBioMembertars:DevelopmentAndRegulatoryMilestoneMember2023-02-012023-02-280001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:LianBioMember2021-03-262023-03-310001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:LianBioMember2023-03-310001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:LianBioMembertars:DevelopmentAndRegulatoryMilestoneMember2023-03-310001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-03-012021-03-310001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-04-012021-06-300001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:LianBioMember2021-04-012021-06-300001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-03-310001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembertars:LianBioMember2023-01-012023-03-310001819790us-gaap:LineOfCreditMember2022-02-022022-02-020001819790us-gaap:LineOfCreditMembertars:CreditFacilityTrancheOneMember2023-01-050001819790tars:CreditFacilityFirstAmendmentTrancheTwoMemberus-gaap:LineOfCreditMember2023-01-050001819790us-gaap:LineOfCreditMember2023-03-152023-03-150001819790tars:LineOfCreditSVBMember2023-03-152023-03-150001819790us-gaap:LineOfCreditMember2023-03-310001819790us-gaap:LineOfCreditMembertars:CreditFacilityTrancheOneMember2023-03-310001819790us-gaap:LineOfCreditMembertars:CreditFacilityTrancheTwoMember2023-03-310001819790tars:CreditFacilityTrancheThreeMemberus-gaap:LineOfCreditMember2023-03-310001819790us-gaap:LineOfCreditMembertars:CreditFacilityTrancheFourMember2023-03-310001819790us-gaap:LineOfCreditMember2022-02-020001819790us-gaap:LineOfCreditMemberus-gaap:PrimeRateMember2022-02-022022-02-020001819790srt:MaximumMemberus-gaap:LineOfCreditMemberus-gaap:PrimeRateMember2022-02-022022-02-020001819790us-gaap:LineOfCreditMember2022-09-302022-09-300001819790us-gaap:LineOfCreditMember2023-01-012023-03-310001819790us-gaap:LineOfCreditMember2022-03-310001819790us-gaap:SubsequentEventMember2023-05-02

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

or

☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to ____ . 

Commission File Number: 001-39614

TARSUS PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Delaware						81-4717861
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

15440 Laguna Canyon Road, Suite 160
Irvine, California						92618
(Address of principal executive offices)						(Zip Code)

(949) 409-9820

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, $0.0001 par value per share			TARS			The Nasdaq Global Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

Emerging growth company

☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 4, 2023, the number of outstanding shares of the registrant's common stock, par value $0.0001 per share, was 26,803,733.

---

Table of Contents

TABLE OF CONTENTS

Part I - Financial Information			1
Item 1. Financial Statements (Unaudited)			1
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations			24
Item 3. Quantitative and Qualitative Disclosures About Market Risk			35
Item 4. Controls and Procedures			35
Part II - Other Information			37
Item 1. Legal Proceedings			37
Item 1A. Risk Factors			37
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			37
Item 3. Defaults Upon Senior Securities			37
Item 4. Mine Safety Disclosures			37
Item 5. Other Information			37
Item 6. Exhibits			38
Signatures			39

---

Table of Contents

PART I—FINANCIAL INFORMATION

Item I. Financial Statements (Unaudited)

TARSUS PHARMACEUTICALS, INC.

INDEX TO THE FINANCIAL STATEMENTS

			Pages
Condensed Balance Sheets			F-2
Condensed Statements of Operations and Comprehensive Loss			F-3
Condensed Statements of Stockholders’ Equity			F-4
Condensed Statements of Cash Flows			F-5
Notes to Condensed Financial Statements			F-6

F-1

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEETS

(In thousands, except share and par value amounts)

 

			March 31, 2023						December 31, 2022
			(unaudited)
ASSETS
Current assets:
Cash and cash equivalents			$	65,997					$	71,660
Marketable securities			135,222						145,366
Accounts receivable			2,500						—
Other receivables			418						3,582
Prepaid expenses			4,509						4,767
Total current assets			208,646						225,375
Property and equipment, net			1,193						957
Operating lease right-of-use assets			540						575
Long-term investments			306						371
Other assets			529						585
Total assets			$	211,214					$	227,863
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other accrued liabilities			$	9,049					$	9,910
Accrued payroll and benefits			4,206						5,519
Total current liabilities			13,255						15,429
Term loan, net			24,515						19,434
Other long-term liabilities			40						100
Total liabilities			37,810						34,963
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding			—						—
Common stock, $0.0001 par value; 200,000,000 shares authorized; 26,800,512 shares issued and outstanding at March 31, 2023 (unaudited); 26,727,458 shares issued and outstanding at December 31, 2022			5						5
Additional paid-in capital			305,651						301,732
Accumulated other comprehensive loss			(70)						(74)
Accumulated deficit			(132,182)						(108,763)
Total stockholders’ equity			173,404						192,900
Total liabilities and stockholders’ equity			$	211,214					$	227,863

See accompanying notes to these unaudited condensed financial statements.

F-2

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share amounts)

									Three Months Ended March 31,
															2023						2022
Revenues:
License fees and collaboration revenue															$	2,500					$	539
Operating expenses:
Cost of license fees and collaboration revenue															—						33
Research and development															12,356						12,081
General and administrative															15,096						7,946
Total operating expenses															27,452						20,060
Loss from operations before other income (expense) and income taxes															(24,952)						(19,521)
Other income (expense):
Interest income															2,293						—
Interest expense															(684)						(316)
Other income (expense), net															6						37
Unrealized loss on equity investments															(65)						(192)
Change in fair value of equity warrants issued by licensee															(17)						(245)
Total other income (expense), net															1,533						(716)
Provision for income taxes															—						(1)
Net loss															$	(23,419)					$	(20,238)
Other comprehensive loss:
Unrealized gain on marketable securities and cash equivalents															4						—
Comprehensive loss															$	(23,415)					$	(20,238)
Net loss per share, basic															$	(0.88)					$	(0.98)
Net loss per share, diluted															$	(0.88)					$	(0.98)
Weighted-average shares outstanding, basic															26,742,023						20,710,224
Weighted-average shares outstanding, diluted															26,742,023						20,710,224

See accompanying notes to these unaudited condensed financial statements.

F-3

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share data)

			Preferred Stock												Common Stock												Additional Paid-In Capital						Accumulated Other Comprehensive Loss						Accumulated Deficit						Total Stockholders’ Equity
			Shares						Amount						Shares						Amount
Balance as of December 31, 2022			—						$	—					26,727,458						$	5					$	301,732					$	(74)					$	(108,763)					$	192,900
Net loss			—						—						—						—						—						—						(23,419)						(23,419)
Recognition of stock-based compensation expense			—						—						—						—						3,906						—						—						3,906
Exercise of vested stock options			—						—						6,443						—						13						—						—						13
Issuance of common stock upon the vesting of restricted stock units			—						—						66,611						—						—						—						—						—
Other comprehensive gain			—						—						—						—						—						4						—						4
Balance as of March 31, 2023			—						$	—					26,800,512						$	5					$	305,651					$	(70)					$	(132,182)					$	173,404

			Preferred Stock												Common Stock												Additional Paid-In Capital						Accumulated Deficit						Total Stockholders’ Equity
			Shares						Amount						Shares						Amount
Balance as of December 31, 2021			—						$	—					20,698,737						$	4					$	213,398					$	(46,672)					$	166,730
Net loss			—						—						—						—						—						(20,238)						(20,238)
Recognition of stock-based compensation expense			—						—						—						—						2,674						—						2,674
Exercise of vested stock options			—						—						225						—						—						—						—
Issuance of common stock upon the vesting of restricted stock units			—						—						4,257						—						—						—						—
Lapse of repurchase obligation for stock option exercises, prior to vesting			—						—						15,309						—						31						—						31
Balance as of March 31, 2022			—						$	—					20,718,528						$	4					$	216,103					(66,910)						$	149,197

See accompanying notes to these unaudited condensed financial statements.

F-4

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

			Three Months Ended March 31,
			2023						2022
Cash Flows From Operating Activities:
Net loss			$	(23,419)					$	(20,238)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			104						41
Accretion of term loan-related costs			81						55
Stock-based compensation			3,906						2,674
Non-cash lease expense			151						113
Unrealized loss on equity investments			65						192
Amortization of discount on available-for-sale debt securities			(1,484)						—
Change in fair value of equity warrants issued by licensee			17						245
Unrealized gain from transactions denominated in a foreign currency			16						1
Changes in operating assets and liabilities:
Accounts receivable			(2,500)						(17)
Other receivables			3,165						(225)
Prepaid expenses			257						926
Other non-current assets			38						14
Accounts payable and other accrued liabilities			(1,046)						1,969
Accrued payroll and benefits			(1,313)						(993)
Other long-term liabilities			(8)						(43)
Net cash used in operating activities			(21,970)						(15,286)
Cash Flows From Investing Activities:
Proceeds from maturities of marketable securities			40,301						—
Purchases of marketable securities			(28,667)						—
Purchases of property and equipment			(340)						(161)
Net cash provided by (used in) investing activities			11,294						(161)
Cash Flows From Financing Activities:
Proceeds from exercise of equity awards			13						—
Proceeds from term loan			5,000						20,000
Payment of term loan issuance costs			—						(815)
Payment of deferred offering costs			—						(60)
Net cash provided by financing activities			5,013						19,125
Net (decrease) increase in cash and cash equivalents			(5,663)						3,678
Cash and cash equivalents — beginning of period			71,660						171,332
Cash and cash equivalents — end of period			$	65,997					$	175,010
Supplemental Disclosures Noncash Investing and Financing Activities:
Operating lease right-of-use asset obtained in exchange for operating lease liability			$	116					$	—
Interest expense paid in cash			$	593					$	127
Additions of property and equipment included within accounts payable and other accrued liabilities			$	—					$	41
Deferred offering costs included within accounts payable and accrued liabilities			$	—					$	55

See accompanying notes to these unaudited condensed financial statements.

F-5

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

1. DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS

Description of Business

Tarsus Pharmaceuticals, Inc. (“Tarsus” or the “Company”) is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The Company’s operations currently consist of its preclinical and clinical studies, corporate administration and commercial leadership supporting planned business growth.

Liquidity

The Company has a limited operating history, no product sales and has accumulated losses and negative cash flows from operations since inception. The Company has funded its inception-to-date operations through equity capital raises; including the Company's initial public offering in 2020 and the follow-on public offering completed in May 2022 (see Note 5), proceeds from its out-license agreement, and draws from its credit facility. The Company estimates that its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q, which have been prepared on a going-concern basis.

Management expects the Company to continue to incur operating losses for the foreseeable future and may be required to raise additional capital to fund its ongoing operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own and/or enter into collaborations and other arrangements to address its liquidity needs, which could materially and adversely affect its business and financial prospects, or even its ability to remain a going concern.

Operating Segment

To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company’s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance. Accordingly, the Company’s management determined that it operates one reportable operating segment.

Emerging Growth Company Status

The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES

(i) Basis of Presentation

The Company’s Condensed Financial Statements have been prepared in conformity with generally accepted accounting principles ("GAAP") in the United States ("U.S.") for interim financial information pursuant to Form 10-Q and with the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 17, 2023.

F-6

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

The interim Condensed Balance Sheet as of March 31, 2023, the interim Condensed Statements of Operations and Comprehensive Loss, the interim Condensed Statements of Stockholders’ Equity, and the interim Condensed Statements of Cash Flows for the three months ended March 31, 2023 and 2022, are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information.

The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March 31, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023 or any other interim or annual period.

The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates.

The Company’s financial statements as of and for the year ended December 31, 2022, reflect the Company’s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.

Certain amounts in the prior years' financial statements have been reclassified to conform to the current year presentation. The Company reclassified license fees revenue and collaboration revenue which were historically separate financial statement line items on the Company's Statements of Operations and Comprehensive Loss and are now presented as a single revenue line— license fees and collaboration revenue. These reclassifications have no impact on total revenue or net loss.

There have been no significant changes in the Company’s significant accounting policies during the three months ended March 31, 2023, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 17, 2023, except as discussed below. The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below.

(ii) Cash and Cash Equivalents

Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value.

(iii) Marketable Securities and Long-Term Investments

Marketable securities consist of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see Note 3). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.

F-7

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other than temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.

Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period.

(iv) Fair Value Measurements

Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:

•Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.

•Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.

•Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The carrying amounts for financial instruments consisting of cash, cash equivalents, short-term marketable securities, long-term investments, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see Note 3).

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.

(v) Property and Equipment, Net

Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from three to five years. Leasehold

F-8

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset’s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March 31, 2023 and 2022.

(vi) Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains cash held in deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"). As of March 31, 2023 and December 2022, the Company held cash and cash equivalents in its depository accounts of $8.1 million and $15.0 million, respectively. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits.

The Company's monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, including SVB. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver, and all of SVB’s deposits and substantially all of SVB’s assets were transferred into a new entity, Silicon Valley Bridge Bank, N.A. (“SVBB”). On March 12, 2023, the Department of the Treasury, the Federal Reserve and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception. Such parties also announced, among other items, that SVBB had assumed the obligations and commitments of former SVB and commitments to advance under existing credit agreements with former SVB will be honored by SVBB pursuant to the terms of such credit agreements. On March 27, 2023, First Citizens Bank assumed all of SVBB’s obligations and commitments, and SVBB began operating as Silicon Valley Bank, a division of First Citizens Bank. Unless otherwise noted herein, all references to SVB or Silicon Valley Bank shall refer to Silicon Valley Bank, a division of First Citizens Bank. In light of the foregoing, the Company does not believe it has exposure to loss as a result of SVB’s receivership.

Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.

(vii) Revenue Recognition for Out-License Arrangements

    

Overview

The Company currently has no product revenue. Reported revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss is associated with one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")— see Note 9. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract’s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period.

The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.

F-9

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales-based threshold milestones, (v) one-time payments for executing drug supply agreements, (vi) development milestone payments, and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.

Contractual Terms for Receipt of Payments

A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract’s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.

The contractual terms that establish the Company’s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows:

(1) Upfront License Fees: The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.

(2) Development Milestones: The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment.

(3) Regulatory Milestones: The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.

(4) Royalties: Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee’s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.

(5) Sales Threshold Milestones: Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt,

F-10

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License.

The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur.

(viii) Research and Development Costs

Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including costs of certain salaries and other employee-related costs (including stock-based compensation), and costs to conduct nonclinical studies, clinical trials and contract manufacturing activities. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.

(ix) Stock-Based Compensation

The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company’s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date.

Stock awards granted typically have one to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award’s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture.

All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within research and development expense or general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management’s judgment, including:

F-11

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

Fair Value of Common Stock — Subsequent to the IPO, the fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant.

Expected Term — The Company’s expected term represents the period that the Company’s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history. 

Expected Volatility — Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.

Risk-Free Interest Rate — The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.

Dividend Yield — The Company’s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.

(x) Net Loss per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable.

Due to a net loss for the three months ended March 31, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.

(xi) Comprehensive Loss

Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.

(xii) Recently Issued or Effective Accounting Standards

Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company’s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company’s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.

3. FAIR VALUE MEASUREMENTS

The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see Note 2(iv)):

F-12

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

			March 31, 2023 Fair Value Measurements
			Level 1						Level 2						Level 3						Total
Assets:
Cash			$	185					$	—					$	—					$	185
Money market funds			65,812						—						—						65,812
U.S. Treasury securities			49,000						—						—						49,000
Commercial paper			—						65,148						—						65,148
Corporate debt securities			—						12,777						—						12,777
Government-related debt securities			—						8,297						—						8,297
Common stock in LianBio			306						—						—						306
Equity warrants (for LianBio shares)			—						—						91						91
Total assets measured at fair value			$	115,303					$	86,222					$	91					$	201,616
			December 31, 2022 Fair Value Measurements
			Level 1						Level 2						Level 3						Total
Assets:
Money market funds			$	64,685					$	—					$	—					$	64,685
U.S. Treasury securities			69,644						—						—						69,644
Commercial paper			—						60,355						—						60,355
Corporate debt securities			—						11,521						—						11,521
Government-related debt securities			—						10,821						—						10,821
Common stock in LianBio			371						—						—						371
Equity warrants (for LianBio shares)			—						—						108						108
Total assets measured at fair value			$	134,700					$	82,697					$	108					$	217,505

Money Market Funds and U.S. Treasury Securities

Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded with readily-available market prices that are publicly observable and independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.

Commercial Paper, Corporate Debt Securities and Government-related Debt Securities

Commercial paper, corporate debt securities and government-related debt securities were valued using Level 2 inputs that utilized industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The Company reviews trading activity and pricing for these investments as of each measurement date.

LianBio Common Stock and Equity Warrants

In March 2021, contemporaneous with the China Out-License transaction (see Note 9), the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, common shares in LianBio at an exercise price equal to common stock par value, which converted into warrants of the parent company of LianBio (LianBio, a pharmaceutical company focused on the Greater China and other Asian markets; Nasdaq: LIAN; any references to common stock or warrants of LianBio shall refer to common stock or warrants of the publicly-traded parent of LianBio) in connection with LianBio's previous Initial Public Offering. The first two tranches were vested and exercised as of December 31, 2022 and converted into 156,746 shares of LianBio common stock as recognized at fair value within long-term investments on the Condensed Balance Sheets as of March 31, 2023 and December 31, 2022. LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price on the Nasdaq Global Market.

The third warrant tranche will vest upon the achievement of a regulatory event and is presented within other assets in the accompanying Condensed Balance Sheets as of March 31, 2023 and December 31, 2022. This warrant tranche remains classified as Level 3 in the fair value hierarchy. The most significant assumptions used in the option pricing valuation model as

F-13

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

of each balance sheet date to determine its fair value included observable and unobservable inputs: LianBio common stock volatility (based on the historical volatility of similar companies), the probability of regulatory milestone achievement for vesting, and the application of an assumed discount rate.

The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:

			Value of equity warrants
Fair value as of December 31, 2022			$	108
Remeasurement of equity warrants			(17)
Fair value as of March 31, 2023			$	91

			Value of equity warrants
Fair value as of December 31, 2021			$	663
Remeasurement of equity warrants			(245)
Fair value as of March 31, 2022			$	418

The fair value and amortized cost of cash, cash equivalents and available-for-sale investments by major security type are presented in the following table:

			March 31, 2023
			Amortized cost						Unrealized gains						Unrealized losses						Estimated fair value
Cash and cash equivalents:
Cash			$	185					$	—					$	—					$	185
Money market funds			65,812						—						—						65,812
Total cash and cash equivalents			$	65,997					$	—					$	—					$	65,997
Marketable securities:
U.S. Treasury securities			$	49,037					$	3					$	(40)					$	49,000
Commercial paper			65,188						4						(44)						65,148
Corporate debt securities			12,773						19						(15)						12,777
Government-related debt securities			8,293						5						(1)						8,297
Total marketable securities			$	135,291					$	31					$	(100)					$	135,222
Long-term investments:
Common stock in LianBio			$	1,231					$	—					$	(925)					$	306
Total long-term investments			$	1,231					$	—					$	(925)					$	306

F-14

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

			December 31, 2022
			Amortized cost						Unrealized gains						Unrealized losses						Estimated fair value
Cash equivalents:
Money market funds			$	64,685					$	—					$	—					$	64,685
Government-related debt securities			4,978						—						—						4,978
Commercial paper			1,997						—						—						1,997
Total cash equivalents			$	71,660					$	—					$	—					$	71,660
Marketable securities:
U.S. Treasury securities			$	69,720					$	5					$	(81)					$	69,644
Commercial paper			58,358						—						—						58,358
Corporate debt securities			11,524						8						(11)						11,521
Government-related debt securities			5,838						5						—						5,843
Total marketable securities			$	145,440					$	18					$	(92)					$	145,366
Long-term investments:
Common stock in LianBio			$	1,231					$	—					$	(860)					$	371
Total long-term investments			$	1,231					$	—					$	(860)					$	371

As of March 31, 2023, substantially all available-for-sale debt securities had a maturity of 12 months or less. Four securities have a contractual maturity between one and four years, with an estimated fair market value of $5.8 million and amortized cost of $5.7 million. As of December 31, 2022, substantially all available-for-sale debt securities had a maturity of 12 months or less. Three securities have a contractual maturity between one and five years, with an estimated fair market value of $4.6 million and amortized cost of $4.6 million. As of March 31, 2023 and December 31, 2022, all available-for-sale debt securities have gross unrealized losses in a continuous loss position for less than one year. As of March 31, 2023 and December 31, 2022, unrealized credit losses on these securities were not material, and accordingly, the Company did not recognize any other-than-temporary impairment losses.

4. BALANCE SHEET ACCOUNT DETAIL

The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below:

Property and Equipment, Net

Property and equipment, net consists of the following:

			March 31, 2023						December 31, 2022
Furniture and fixtures			$	891					$	714
Office equipment			215						197
Laboratory equipment			167						167
Leasehold improvements			569						425
Property and equipment, at cost			1,842						1,503
(Less): Accumulated depreciation and amortization			649						546
Property and equipment, net			$	1,193					$	957

Depreciation expense for the three months ended March 31, 2023 and 2022 was $0.1 million and $0.1 million, respectively.

F-15

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

Accounts Payable and Other Accrued Liabilities 

Accounts payable and other accrued liabilities consists of the following:

			March 31, 2023						December 31, 2022
Trade accounts payable and other			$	7,566					$	5,269
Accrued clinical studies			542						3,691
Operating lease liability, current			703						721
Accrued interest, current			224						215
Income taxes payable			14						14
Accounts payable and other accrued liabilities			$	9,049					$	9,910

5. STOCKHOLDERS’ EQUITY

Follow-On Public Offering

In May 2022, the Company completed a follow-on public offering under its Shelf Registration Statement for an initial underwritten sale of 5,600,000 shares of its common stock at a price of $13.50 per share. The Company also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of its common stock at the public offering price. In June 2022, the underwriters partially exercised this option and the Company's sale of additional 289,832 shares at $13.50 per share was concurrently completed.

Total gross proceeds from this offering were $79.5 million (before underwriting discounts, commissions and other estimated offering expenses), resulting in net proceeds of $74.3 million.

Common Stock Outstanding and Reserves for Future Issuance

As of March 31, 2023 and December 31, 2022, the Company had 26.8 million and 26.7 million, respectively, of common stock issued and outstanding. Each share of common stock is entitled to one vote.

The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:

			March 31, 2023						December 31, 2022
Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans			8,068,595						8,346,738
Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan			2,930,594						2,663,319
Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans			4,596,414						3,899,342
Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan			1,128,373						551,258
Total shares of common stock reserved			16,723,976						15,460,657

F-16

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

6. STOCK-BASED COMPENSATION

Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022 as follows:

									Three Months Ended March 31,
															2023						2022
Research and development															$	1,163					$	678
General and administrative															2,743						1,996
Total stock-based compensation															$	3,906					$	2,674

The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:

						Three Months Ended March 31,
						2023						2022
Weighted average risk-free interest rate						4.20		%				1.86		%
Weighted average volatility						71.9		%				77.7		%
Expected term (in years)						6.25						6.25
Dividend yield rate						—		%				—		%
Weighted-average grant-date fair value per stock option						$	15.07					$	19.71

Stock Option Activity

Stock option activity during the three months ended March 31, 2023 was as follows:

						Number of Shares						Weighted- Average Exercise Price/Share						Weighted- Average Remaining Contractual Term (Years)						Aggregate Intrinsic Value(1)
Outstanding - December 31, 2022						3,899,342						$	16.69					8.07						$	19,196
Granted						728,169						15.07
Exercised						(6,443)						2.01
Forfeited						(24,654)						21.19
Outstanding— March 31, 2023						4,596,414						$	16.43					8.16						$	15,316
Exercisable— March 31, 2023						2,028,011						$	14.26					7.30						$	12,045
Unvested—March 31, 2023						2,568,403						$	18.15					8.83						$	3,271

(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock as of March 31, 2023.

As of March 31, 2023, there was approximately $29.8 million of unrecorded compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average period of 2.5 years.

Restricted Stock Unit Activity

Restricted stock unit activity during the three months ended March 31, 2023 was as follows:

F-17

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

						Number of Shares						Weighted- Average Exercise Price/Share
Outstanding - December 31, 2022						551,258						$	17.78
Granted						647,768						15.24
Vested						(66,611)						19.15
Forfeited						(4,042)						19.40
Outstanding— March 31, 2023						1,128,373						$	16.24

As of March 31, 2023, there was approximately $16.8 million of unrecorded compensation expense related to unvested restricted stock units, which the Company expects to recognize over a weighted average period of 3.5 years.

7. NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per share:

									Three Months Ended March 31,
															2023						2022
Net loss															$	(23,419)					$	(20,238)
Weighted-average shares outstanding—basic and diluted															26,742,023						20,710,224
Net loss per share—basic and diluted															$	(0.88)					$	(0.98)

The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:

									Three Months Ended March 31,
															2023						2022
Stock options, unexercised—vested and unvested															4,596,414						3,561,261
Restricted stock units—unvested															1,128,373						351,422
Stock options exercised prior to vesting— remaining unvested															—						12,531
Total															5,724,787						3,925,214

8. COMMITMENTS & CONTINGENCIES

In-License Agreements for Lotilaner

January 2019 Agreement for Skin and Eye Disease or Conditions in Humans

In January 2019, the Company executed a license agreement with Elanco Tiergesundheit AG (“Elanco”) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.

The Company's made cash payments to Elanco under the Eye and Derm Agreement comprised of $1.0 million upfront upon contract execution in January 2019 and a total of $3.0 million for two specified clinical milestone achievements in September 2020 and April 2021, respectively.

F-18

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

In March 2023, a clinical milestone was triggered to Elanco under the Eye and Derm Agreement upon enrollment of the first patient in the Phase 2a Galatea trial, evaluating the potential treatment of rosacea. The related milestone of $1.0 million was included in research and development expense on the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023. The milestone achievement fully offset a $0.6 million remaining prepayment and $0.4 million was recognized in accounts payable and other accrued liabilities on the accompanying Condensed Balance Sheets as of March 31, 2023.

As of March 31, 2023, the Company is obligated to make further cash payments to Elanco of $2.4 million under the Eye and Derm Elanco Agreement upon achievement of the last clinical milestone in the treatment of human skin diseases using lotilaner and a maximum of $79.0 million for various commercial and sales threshold milestones for the treatment of human skin diseases and the treatment of blepharitis in humans using lotilaner. In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.

September 2020 Agreement for All Other Diseases or Conditions in Humans

In September 2020, the Company executed a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement"). In September 2020, the Company issued Elanco 222,460 shares of its common stock with an estimated fair value of $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).

The Company's made cash payments under the All Human Uses Elanco Agreement of $0.5 million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the treatment of Lyme disease. The Company is required to make further cash payments under this agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.0 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net product sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.

Employment Agreements

The Company has entered into employment agreements with seven of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.

Consulting Agreements

The Company has a preexisting consulting agreement with a board member that was appointed in December 2021. This consulting agreement provides for annual cash compensation of approximately $0.2 million and option grants to purchase 45,134 shares of the Company’s common stock, with exercise prices ranging from $2.01 to $34.72 per share. This consulting agreement may be terminated by either party with ten days notice and contains standard confidentiality, indemnification, and intellectual property assignment provisions in favor of the Company.

Separation Agreement

On May 4, 2023, the Company entered into a separation and severance agreement with its former Chief Financial Officer, which provides for the following benefits effective upon and after June 15, 2023: severance payments equal to nine months of base salary and 10 months of company-paid continued benefits coverage, a lump sum bonus payment payable in 2024 equal to one-third of the former Chief Financial Officer's 2023 annual target bonus adjusted based on the 2023 Company performance score, accelerated vesting of options in 40,744 shares of the Company’s common stock, and an option exercise

F-19

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

period extension for certain options, in exchange for a release and waiver of claims and continued compliance with his confidentiality obligations.

Litigation Contingencies

From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.

Indemnities and Guarantees

The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.

9. OUT-LICENSE AGREEMENT

Out-License of TP-03 Commercial Rights in the China Territory in March 2021

On March 26, 2021, the Company entered into The China Out-License agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the China Territory, as defined in the agreement, for the treatment of Demodex blepharitis and Meibomian Gland Disease. LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.

The Company assessed this arrangement in accordance with ASC 606 and identified the following material promises under the arrangement: (i) the exclusive license to research, develop, manufacture, commercialize, make, offer for sale, sell, and import TP-03 in the China Territory, and (ii) the research and development services in the form of clinical study materials for the respective Phase 2b/3 trial (Saturn-1) and Phase 3 (Saturn-2) TP-03 trials. The promises to provide research and development services for Saturn-1 and Saturn-2 clinical trials were evaluated and determined to be distinct promises in the contract and each of the two clinical trials are separate performance obligations apart from the promise to provide the license.

The assessment of the initial transaction price for the China Out-License agreement included an analysis of amounts the Company expected to receive, which at contract inception consisted of: (i) the upfront cash payment of $15.0 million, (ii) a second cash payment of $10.0 million, (iii) a $10.0 million milestone that was determined to be within the control of the Company, and (iv) $1.2 million representing the initial fair value of the equity warrant.

The Company accounted for each performance obligation as follows:

Out-License

The Company determined that this license was distinct based on an evaluation of the delivery of the functional license that was in the later stages of development, and it met the criteria for being distinct from the research and development services required under the China Out-License agreement. The Company determined the standalone selling price of this license using a discounted projected sales model and recognized as license fees and collaboration revenue the total allocated transaction price at contract inception, upon delivery of the license.

Research and Development Services

The standalone selling price of these performance obligations was determined using the adjusted market assessment approach. The Company analyzed costs expected to be incurred for each of the clinical trials through completion to estimate the price that a customer would be willing to pay for these services in order to benefit from the clinical trials. The Company determined that LianBio simultaneously benefited from the research and development services that are satisfied over time, as they were able to request and access the clinical trial data at any point through the trial completion. Therefore, the Company recognized the amounts allocated to the respective research and development performance obligations for Saturn-1 and Saturn-2

F-20

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

as the research and development services were provided using an input method, based on the costs incurred for each clinical trial and the total costs expected to be incurred to satisfy each performance obligation. The Company believes this method most faithfully depicted its performance in transferring the promised services during the expected period of time that each clinical trial was ongoing. The Company monitored the expected completion dates for each clinical trial and updated its estimated time to completion at each reporting period, as necessary.

In February 2023, a specified milestone event was triggered resulting in $2.5 million recognized as license fees and collaboration revenue in the Condensed Statements of Operations for the three months ended March 31, 2023. This cash payment was received in the second quarter of 2023. Through March 31, 2023, the Company had received payments from LianBio totaling $80.0 million, comprised of initial consideration of $15.0 million and $65.0 million for the achievement of specified milestones.

As of March 31, 2023 the Company is eligible to receive further consideration from LianBio upon the achievement of additional TP-03 events, including: (i) additional regulatory milestone and one-time payments of up to an aggregate of $25.0 million (including the $2.5 million cash payment received in the second quarter of 2023), (ii) China-Based TP-03 sales threshold milestone payments of up to an aggregate of $100.0 million, (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales, and (iv) vesting of a LianBio equity warrant upon certain regulatory milestones.

Revenue recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss relates to the satisfaction of performance obligations including (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the completion of U.S. clinical activities and then providing LianBio with the related data to supplement its local pivotal trial package for TP-03 in the treatment of Demodex blepharitis.

As part of the China Out-License with LianBio the Company granted Elanco an additional 187,500 shares of the Company's common stock that otherwise would have been issuable no later than the 18-month anniversary of the All Human Uses Elanco Agreement for its continued license exclusivity. These issued shares were valued at $5.5 million, based on the Company's closing stock price of $29.30 per share on the date this issuance became contractually required.

The Company made a contractual payment in the amount of $2.5 million to Elanco following the receipt of $25 million of proceeds from LianBio during the second quarter of 2021. During the fourth quarter of 2022, the Company recognized $0.4 million of cost of license fees and collaboration revenue upon receipt of $10 million of cash proceeds from LianBio for the achievement of a clinical development milestone.

The expenses recognized under the China-Out License were not material for the three month periods ended March 31, 2023 and 2022.

10. CREDIT FACILITY AGREEMENT

On February 2, 2022, the Company executed the Credit Facility with Hercules Capital, Inc. ("Hercules") and SVB that expires on February 2, 2027. Concurrent with the execution of the Credit Facility, the Company made a $20.0 million draw.

On January 5, 2023, the Company entered into an amendment to the loan and security agreement (the "First Amendment"). The First Amendment set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions, including an extended period for the Company to draw down the $25.0 million tranche associated with the New Drug Application ("NDA") submission, from March 15, 2023 to March 15, 2024, provided at least $5.0 million was drawn on or before March 15, 2023 and at least an additional $5 million is drawn on or before September 15, 2023. The Company did not incur any lender fees as part of this First Amendment.

On March 15, 2023, the Company made a $5.0 million draw (including SVB's commitment of $1.25 million) from the $25.0 million tranche that became available upon submission of the NDA. As of March 31, 2023, the Credit Facility provides for a remaining aggregate principal amount of up to $130.0 million with tranched availability as follows: $20.0 million currently available related to the Company's NDA submission with the FDA for TP-03 in September 2022, $35.0 million available upon FDA approval of TP-03, $50.0 million available upon achievement of product net revenue thresholds, and $25.0 million available upon lender approval.

F-21

---

Table of Contents

TARSUS PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)

(Unaudited)

Each of these tranches may be drawn down in $5.0 million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry.

Under the First Amendment, the outstanding principal draws accrue interest at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus 4.45% with an aggregate cap of 11.45%, or (ii) 8.45%. At the execution date of the Credit Facility, the WSJ prime rate was 3.25% and increased to 8.00% as of March 31, 2023.

The Company is required to pay a specified fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.2 million was derived by multiplying 4.75% by the $25.0 million outstanding principal balance as of March 31, 2023 and is accreted to interest expense through maturity.

As of March 31, 2023 and 2022, the effective interest rate for the full term of the Credit Facility was 12.12% and 9.66%, respectively.

During the three months ended March 31, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:

															Three Months Ended March 31, 2023						Three Months Ended March 31, 2022
Interest expense for term loan															$	602					$	274
Accretion of end of term charge															53						32
Amortization of debt issuance costs															29						23
Total interest expense related to term loan															$	684					$	329

The carrying value of the Credit Facility consists of principal outstanding less legal and administrative issuance costs that were recorded as a debt discount to the term loan, net and will continue to be accreted to interest expense using the effective interest method during its term. The principal balance of this Credit Facility and related accretion and amortization as of March 31, 2023 and December 31, 2022 are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:

			March 31, 2023						December 31, 2022
Term loan, gross			$	25,000					$	20,000
Debt issuance costs			(875)						(875)
Accretion of end of term charge			226						174
Accumulated amortization of debt issuance costs			164